Patent US4831390A successfully refreshed from Google Patents.
Patent US4835103A successfully refreshed from Google Patents.
US4835103A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Differential binding of membrane potential sensitive materials to lymphocytes
Assignee: Individual
•
Filing: 1986-11-24
•
Granted: 1989-05-30
•
Expires: 2006-11-24
Abstract
Abstract The method of the present invention comprises contacting a suspension of viable lymphocytes with a solution containing a membrane potential sensitive fluorescent dye. The contact between the lymphocyte suspension and the MPS dye is maintained for sufficient time to permit labelling of the lymphocytes by the MPS dye material. The labelled lymphocytes are passed individually through a focused source of excitation energy causing any MPS dye material to fluoresce. The fluorescent emission from each cell is recorded as a pulse and the number of pulses of each intensity are recorded. The distribution of the number of pulses versus the intensity is prepared distribution is bimodal. A first peak includes pulses of low fluorescence intensity and a second peak comprises pulses of high fluorescence intensity. A ratio of the total counts of low fluorescence intensity to the total counts of high fluorescence intensity produces a factor which distinguishes lymphocytes derived from bodies afflicted with malignancy from bodies which are not afflicted with malignancy.
Inventors
- 👤 Boris Cercek
- 👤 Lea Cercek
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 05:04
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/569; G01N33/56966; G01N33/56972; G01N33/5005; G01N33/5091; G01N21/00; G01N21/62; G01N21/63; G01N21/64; G01N21/6428; G01N2021/6439
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
179 words
A method for the determination of a malignancy in a human or animal body comprising the steps of: (a) obtaining a fraction consisting essentially of SMM-responding lymphocytes derived from a sample of blood from said body; (b) labelling said lymphocytes by contacting a suspension of said lymphocytes with a fluorescent cell membrane potential sensitive material such that said membrane potential sensitive material is bound to said lymphocytes; (c) causing said lymphocytes to pass individually through a focused source of fluorescence excitation energy causing said membrane potentail sensitive material to fluoresce; (d) measuring the intensity of the fluorescence emission from each of said lymphocytes; and (e) forming a bimodal distribution curve based on the measured intensity of the fluorescence emission of said lymphocytes and determining a ratio therefrom of the number of lymphocytes of lower fluorescence intensities to the number of lymphocytes of higher fluorescence intensities, said ratio then being compared to a predetermined cutoff value, such that when said ratio is lower than the predetermined cutoff value it is indicative of the presence of a malignancy in said body.
Claim 2
Independent Claim
179 words
A method for the determination of a malignancy in a human or animal body comprising the steps of: (a) obtaining a fraction consisting essentially of SMM-responding lymphocytes derived from a sample of blood from said body; (b) labelling said lymphocytes by contacting a suspension of said lymphocytes with a fluorescent cell membrane potential sensitive material such that said membrane potential sensitive material is bound to said lymphocytes; (c) causing said lymphocytes to pass individually through a focused source of fluorescence excitation energy causing said membrane potentail sensitive material to fluoresce; (d) measuring the intensity of the fluorescence emission from each of said lymphocytes; and (e) forming a bimodal distribution curve based on the measured intensity of the fluorescence emission of said lymphocytes and determining a ratio therefrom of the number of lymphocytes of lower fluorescence intensities to the number of lymphocytes of higher fluorescence intensities, said ratio then being compared to a predetermined cutoff value, such that when said ratio is lower than the predetermined cutoff value it is indicative of the presence of a malignancy in said body.
Claim 3
Dependent Claim
30 words
The method of claim 1 wherein said membrane potential sensitive material is a fluorescent dye selected from the group consisting of the cyanine dyes, merocyanine dyes and the oxonol dyes.
Claim 4
Dependent Claim
25 words
The method of claim 2 wherein said membrane sensitive material is a cyanine dye selected from the group consisting of carbocyanine, dicarbocyanine and tricarbocyanine dyes.
Claim 5
Dependent Claim
13 words
The method of claim 3 wherein said membrane potential sensitive material is 3,3'-dihexyloxacarbocyanine.
Claim 6
Dependent Claim
29 words
The method of claim 1 wherein said suspension of lymphocytes is in phosphate buffered saline solution and comprises about 2×10 6 cells per milliliter of phosphate buffered saline solution.
Claim 7
Dependent Claim
74 words
The method of claim 1 wherein said suspension of lymphocytes is mixed with equal parts by volume of a solution comprising about 2.86×10 -6 g/ml of said membrane potential sensitive material in phosphate buffered saline solution and maintaining said mixture for sufficient time to effect binding of a sufficient quantity of said material to said lymphocytes to cause said lymphocytes to emit fluorescence when passed individually through said focused source of fluorescence excitation energy.
Claim 8
Dependent Claim
16 words
The method of claim 6 wherein said mixture is maintained for at least about 10 minutes.
Claim 9
Dependent Claim
15 words
The method of claim 1 wherein said source of excitation energy is a laser beam.
Claim 10
Dependent Claim
15 words
The method of claim 8 wherein said laser beam has a wavelength of 488 nm.
Claim 11
Dependent Claim
59 words
The method of claim 1 wherein said labeled lymphocytes are injected into a flowing stream of a compatible sheath fluid and a laminar, coaxial flow of said lymphocytes and said sheath fluid is established whereby said lymphocytes are constrained as individual cells in the center portion of said flowing stream prior to passing through said source of excitation energy.
Claim 12
Dependent Claim
73 words
The method of claim 1 wherein the intensity of fluorescence emissions from each of said lymphocytes is converted to an electrical pulse, the height of which is directly related to the intensity of the emission, and plotted on a distribution curve with pulse height as the abscissa and pulse counts as the ordinate, said distribution curve being bimodal with one peak representing lower intensity emissions and the other peak representing higher intensity emissions.
Claim 13
Dependent Claim
58 words
The method of claim 11 wherein the number of pulses in the peak representing higher intensity emissions is divided into the number of pulses in the peak representing lower intensity emission to obtain an alpha factor that is characteristic for lymphocytes derived from a body afflicted with a malignancy and for lymphocytes derived from a malignancy free body.
Claim 14
Dependent Claim
39 words
The method of claim 12 wherein lymphocytes derived from a body afflicted with a malignancy have an alpha factor of less than 2.6 , and lymphocytes derived from a malignancy-free body have an alpha factor of greater than 2.6.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-05-29 | 1992-11-28 | 1993-05-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-05-29 | 1996-11-28 | 1997-05-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-05-29 | 2000-11-28 | 2001-05-30 | $7700.00 | Window Closed / Lapsed |